BRPI0113155C1 - métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b - Google Patents
métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite bInfo
- Publication number
- BRPI0113155C1 BRPI0113155C1 BRPI0113155A BR0113155A BRPI0113155C1 BR PI0113155 C1 BRPI0113155 C1 BR PI0113155C1 BR PI0113155 A BRPI0113155 A BR PI0113155A BR 0113155 A BR0113155 A BR 0113155A BR PI0113155 C1 BRPI0113155 C1 BR PI0113155C1
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- vaccine
- producing
- methods
- surface antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 7
- 102000036639 antigens Human genes 0.000 title abstract 7
- 108091007433 antigens Proteins 0.000 title abstract 7
- 208000006454 hepatitis Diseases 0.000 title abstract 5
- 231100000283 hepatitis Toxicity 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 title abstract 2
- 229940124736 hepatitis-B vaccine Drugs 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0019728.5A GB0019728D0 (en) | 2000-08-10 | 2000-08-10 | Novel treatment |
| GB0101334A GB0101334D0 (en) | 2001-01-18 | 2001-01-18 | Novel compounds |
| PCT/EP2001/009100 WO2002012287A1 (en) | 2000-08-10 | 2001-08-07 | Purification of hbv antigens for use in vaccines |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BR0113155A BR0113155A (pt) | 2003-07-08 |
| BRPI0113155B1 BRPI0113155B1 (pt) | 2018-11-21 |
| BRPI0113155B8 BRPI0113155B8 (pt) | 2019-08-13 |
| BRPI0113155C1 true BRPI0113155C1 (pt) | 2021-05-25 |
Family
ID=26244821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0113155A BRPI0113155C1 (pt) | 2000-08-10 | 2001-08-07 | métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20030235590A1 (OSRAM) |
| EP (2) | EP1307473B1 (OSRAM) |
| JP (2) | JP2004505992A (OSRAM) |
| KR (1) | KR100804922B1 (OSRAM) |
| CN (1) | CN1468256B (OSRAM) |
| AP (1) | AP2003002734A0 (OSRAM) |
| AR (1) | AR030325A1 (OSRAM) |
| AT (2) | ATE313558T1 (OSRAM) |
| AU (2) | AU2001282073B2 (OSRAM) |
| BG (1) | BG66038B1 (OSRAM) |
| BR (1) | BRPI0113155C1 (OSRAM) |
| CA (2) | CA2427475C (OSRAM) |
| CY (2) | CY1106310T1 (OSRAM) |
| CZ (1) | CZ303217B6 (OSRAM) |
| DE (2) | DE60136400D1 (OSRAM) |
| DK (2) | DK1307473T3 (OSRAM) |
| DZ (1) | DZ3470A1 (OSRAM) |
| EA (1) | EA006433B1 (OSRAM) |
| EG (1) | EG25829A (OSRAM) |
| ES (2) | ES2314555T3 (OSRAM) |
| HU (1) | HU228932B1 (OSRAM) |
| IL (2) | IL154301A0 (OSRAM) |
| MX (1) | MXPA03001235A (OSRAM) |
| MY (1) | MY128999A (OSRAM) |
| NO (1) | NO20030635L (OSRAM) |
| NZ (1) | NZ524012A (OSRAM) |
| OA (1) | OA12361A (OSRAM) |
| PE (1) | PE20020287A1 (OSRAM) |
| PL (1) | PL204736B1 (OSRAM) |
| PT (1) | PT1666487E (OSRAM) |
| SI (2) | SI1666487T1 (OSRAM) |
| SK (2) | SK288079B6 (OSRAM) |
| UA (1) | UA79735C2 (OSRAM) |
| UY (1) | UY26882A1 (OSRAM) |
| WO (1) | WO2002012287A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA79735C2 (uk) * | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
| GB0202901D0 (en) * | 2002-02-07 | 2002-03-27 | Glaxosmithkline Biolog Sa | Novel vaccine |
| JP2009500454A (ja) * | 2005-07-11 | 2009-01-08 | グローブイミューン， インコーポレイテッド | 標的化治療の変異型を回避する免疫応答を惹起するための組成物および方法 |
| AP2745A (en) * | 2005-08-02 | 2013-09-30 | Novartis Vaccines & Diagnostic | Reducing interference between oil-containing adjuvants and surfactant-containing antigens |
| GB0522765D0 (en) * | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
| GB0612142D0 (en) | 2006-06-20 | 2006-08-02 | Secr Defence | Spreading modulation spectrum control |
| CN103585624A (zh) | 2006-09-07 | 2014-02-19 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗 |
| EP2142211A1 (en) | 2007-05-02 | 2010-01-13 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| CN101803189B (zh) * | 2007-10-30 | 2014-01-08 | 京瓷株式会社 | 弹性波装置 |
| US8250102B2 (en) * | 2008-03-14 | 2012-08-21 | Microsoft Corporation | Remote storage and management of binary object data |
| KR100959145B1 (ko) | 2008-03-21 | 2010-05-25 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법 |
| US9415006B2 (en) * | 2008-05-23 | 2016-08-16 | The Regents Of The University Of Michigan | Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same |
| CN102459324B (zh) * | 2009-05-27 | 2014-07-09 | 葛兰素史密丝克莱恩生物有限公司 | Casb7439构建体 |
| PT2705365T (pt) * | 2011-01-14 | 2016-09-19 | Hal Allergy Holding B V | Imunoensaio para determinação direta do teor de antigénio de produtos compreendendo partículas de antigénio acoplado a adjuvante |
| GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| CN106222129A (zh) * | 2016-07-29 | 2016-12-14 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
| JP7404226B2 (ja) | 2017-07-18 | 2023-12-25 | セラム インスティテュート オブ インディア プライベート リミティド | 向上した安定性、高度の免疫原性、及び減少した反応源性を有する免疫原性組成物、並びにその調製プロセス |
| GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| JP2022524007A (ja) | 2019-03-05 | 2022-04-27 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｂ型肝炎免疫化レジメンおよび組成物 |
| AU2020403296B2 (en) * | 2019-12-13 | 2025-03-06 | Grand Theravac Life Science (Nanjing) Co., Ltd. | Immunostimulatory composition and use thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1030777A (en) * | 1963-12-06 | 1966-05-25 | Ciba Ltd | Method of preparing a vaccine against trypanosoma cruzi infections |
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4720385A (en) * | 1983-03-29 | 1988-01-19 | Miles Laboratories, Inc. | Protein compositions substantially free from infectious agents |
| JPS6013718A (ja) | 1983-07-05 | 1985-01-24 | Chemo Sero Therapeut Res Inst | Ｂ型肝炎ワクチン |
| KR850001534A (ko) | 1983-08-22 | 1985-03-30 | 제임스 에프. 나우톤 | 형질전환된 효모로 부터 유도된 면역원성 HBsAg |
| US4683294A (en) * | 1985-04-03 | 1987-07-28 | Smith Kline Rit, S.A. | Process for the extraction and purification of proteins from culture media producing them |
| FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
| US4649192A (en) * | 1985-05-30 | 1987-03-10 | Smith Kline-Rit | Method for the isolation and purification of hepatitis B surface antigen using polysorbate |
| US4895800A (en) | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
| AP56A (en) | 1987-01-30 | 1989-09-26 | Smithkline Biologicals S A | Hepatitis B virus surface antigens and hybrid antigehs containing them. |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| EP0304578B1 (en) | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide comprising hepatitis B surface antigen |
| ES2056799T3 (es) | 1987-07-17 | 1994-10-16 | Rhein Biotech Ges Fur Biotechn | Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso. |
| EP0314240A3 (en) * | 1987-10-26 | 1990-03-28 | Merck & Co. Inc. | Process for purifying recombinant hepatitis antigens |
| JPH085804B2 (ja) | 1988-04-28 | 1996-01-24 | 財団法人化学及血清療法研究所 | Ａ型及びｂ型肝炎混合アジュバントワクチン |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5242812A (en) * | 1989-02-07 | 1993-09-07 | Bio-Technology General Corp. | Method for production and purification of hepatitis B vaccine |
| US5274081A (en) * | 1989-09-20 | 1993-12-28 | Immuno A.G. | Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen |
| GB9007024D0 (en) | 1990-03-29 | 1990-05-30 | Imperial College | Novel vaccine |
| WO1992011291A1 (en) | 1990-12-20 | 1992-07-09 | Smithkline Beecham Biologicals (S.A.) | Vaccines based on hepatitis b surface antigen |
| JP3026029B2 (ja) | 1991-04-26 | 2000-03-27 | 財団法人阪大微生物病研究会 | 組換え水痘ウイルスとその作製法 |
| JPH06503231A (ja) | 1991-09-18 | 1994-04-14 | アムジエン・インコーポレーテツド | 胆汁酸塩を含有するｂ型肝炎ワクチン製剤 |
| US6620414B2 (en) * | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
| EP0671948B1 (en) | 1992-06-25 | 1997-08-13 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| JP3468773B2 (ja) | 1994-07-15 | 2003-11-17 | ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫調節オリゴヌクレオチド |
| EP0796326A4 (en) * | 1994-10-24 | 2000-01-19 | Ophidian Pharm Inc | VACCINE AND ANTITOXIN FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE DISEASE |
| KR960023066A (ko) * | 1994-12-10 | 1996-07-18 | 성재갑 | 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법 |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| TR200002608T2 (tr) * | 1998-03-09 | 2000-11-21 | Smithkline Beecham Biologicals S.A | Kombine aşı kompozisyonları |
| DE69929444T2 (de) | 1998-08-10 | 2006-09-28 | Antigenics Inc., Woburn | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung |
| JP2002532116A (ja) * | 1998-12-23 | 2002-10-02 | メルク エンド カムパニー インコーポレーテッド | 改良された組換えｂ型肝炎表面抗原 |
| UA79735C2 (uk) * | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
-
2001
- 2001-07-08 UA UA2003021025A patent/UA79735C2/uk unknown
- 2001-08-07 AP APAP/P/2003/002734A patent/AP2003002734A0/en unknown
- 2001-08-07 EA EA200300129A patent/EA006433B1/ru not_active IP Right Cessation
- 2001-08-07 DK DK01960630T patent/DK1307473T3/da active
- 2001-08-07 AT AT01960630T patent/ATE313558T1/de active
- 2001-08-07 OA OA1200300038A patent/OA12361A/en unknown
- 2001-08-07 AT AT05077471T patent/ATE412665T1/de active
- 2001-08-07 SI SI200130884T patent/SI1666487T1/sl unknown
- 2001-08-07 DZ DZ013470A patent/DZ3470A1/fr active
- 2001-08-07 CN CN018169988A patent/CN1468256B/zh not_active Expired - Lifetime
- 2001-08-07 CA CA2427475A patent/CA2427475C/en not_active Expired - Lifetime
- 2001-08-07 AU AU2001282073A patent/AU2001282073B2/en not_active Expired
- 2001-08-07 ES ES05077471T patent/ES2314555T3/es not_active Expired - Lifetime
- 2001-08-07 SK SK50032-2012A patent/SK288079B6/sk not_active IP Right Cessation
- 2001-08-07 KR KR1020037001933A patent/KR100804922B1/ko not_active Expired - Lifetime
- 2001-08-07 EP EP01960630A patent/EP1307473B1/en not_active Expired - Lifetime
- 2001-08-07 ES ES01960630T patent/ES2254464T3/es not_active Expired - Lifetime
- 2001-08-07 JP JP2002518258A patent/JP2004505992A/ja active Pending
- 2001-08-07 CA CA2740282A patent/CA2740282A1/en not_active Abandoned
- 2001-08-07 WO PCT/EP2001/009100 patent/WO2002012287A1/en not_active Ceased
- 2001-08-07 IL IL15430101A patent/IL154301A0/xx unknown
- 2001-08-07 CZ CZ20030385A patent/CZ303217B6/cs not_active IP Right Cessation
- 2001-08-07 DE DE60136400T patent/DE60136400D1/de not_active Expired - Lifetime
- 2001-08-07 MX MXPA03001235A patent/MXPA03001235A/es active IP Right Grant
- 2001-08-07 SI SI200130489T patent/SI1307473T1/sl unknown
- 2001-08-07 SK SK169-2003A patent/SK288069B6/sk not_active IP Right Cessation
- 2001-08-07 BR BRPI0113155A patent/BRPI0113155C1/pt not_active IP Right Cessation
- 2001-08-07 DE DE60116107T patent/DE60116107T2/de not_active Expired - Lifetime
- 2001-08-07 HU HU0302951A patent/HU228932B1/hu not_active IP Right Cessation
- 2001-08-07 PT PT05077471T patent/PT1666487E/pt unknown
- 2001-08-07 DK DK05077471T patent/DK1666487T3/da active
- 2001-08-07 AU AU8207301A patent/AU8207301A/xx active Pending
- 2001-08-07 US US10/344,211 patent/US20030235590A1/en not_active Abandoned
- 2001-08-07 NZ NZ524012A patent/NZ524012A/en unknown
- 2001-08-07 EP EP05077471A patent/EP1666487B1/en not_active Expired - Lifetime
- 2001-08-07 PL PL362322A patent/PL204736B1/pl unknown
- 2001-08-08 EG EG2001080869A patent/EG25829A/xx active
- 2001-08-08 PE PE2001000786A patent/PE20020287A1/es not_active Application Discontinuation
- 2001-08-08 AR ARP010103790A patent/AR030325A1/es active IP Right Grant
- 2001-08-10 UY UY26882A patent/UY26882A1/es not_active Application Discontinuation
- 2001-08-10 MY MYPI20013779A patent/MY128999A/en unknown
-
2003
- 2003-02-05 IL IL154301A patent/IL154301A/en active IP Right Grant
- 2003-02-07 BG BG107545A patent/BG66038B1/bg unknown
- 2003-02-07 NO NO20030635A patent/NO20030635L/no unknown
-
2005
- 2005-11-03 US US11/266,565 patent/US20060159705A1/en not_active Abandoned
-
2006
- 2006-03-07 CY CY20061100311T patent/CY1106310T1/el unknown
-
2008
- 2008-12-10 CY CY20081101440T patent/CY1108789T1/el unknown
- 2008-12-23 US US12/342,220 patent/US8624004B2/en not_active Expired - Lifetime
-
2012
- 2012-08-16 JP JP2012180462A patent/JP5559847B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0113155C1 (pt) | métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b | |
| ATE350057T1 (de) | Impfstoffzusammesetzung | |
| DE60121136D1 (de) | Proteasom-influenzavirus-impfstoffzusammensetzung | |
| DK1090033T3 (da) | Partikler af HCV-kappeproteiner: Anvendelse til vaccination | |
| BR0114393A (pt) | Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado | |
| AR014182A1 (es) | Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones | |
| AU6616301A (en) | Modification of hepatitis b core antigen | |
| NZ545048A (en) | Chimeric antigens for breaking host tolerance to foreign antigens | |
| BRPI0206565A8 (pt) | Composições e seus usos, e processo de produção de um arranjo de antígeno ordenado e repetitivo, de ocorrência não-natural | |
| BRPI0707779B8 (pt) | antígeno isolado, composição de vacina e método para produção de uma proteína antígeno | |
| CY1108147T1 (el) | Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων | |
| MX9401225A (es) | Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion. | |
| ATE511855T1 (de) | Adjuvansformulierung zur scheimhaut-applikation | |
| ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
| DE60136360D1 (de) | Antigen aus streptococcus pyogenes | |
| DE60222296D1 (de) | Impfstoff von umhüllten viren und verfahren zu seiner herstellung | |
| SE9903534D0 (sv) | Vaccin | |
| ATE303821T1 (de) | Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus | |
| ES2155510T3 (es) | Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion. | |
| TW200734463A (en) | Marked bovine viral diarrhea virus vaccines | |
| ATE353226T1 (de) | Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form | |
| ECSP034474A (es) | Nuevo tratamiento | |
| DE60036563D1 (de) | Nukleoprotein des toscanavirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2498 DE 21/11/2018, QUANTO AO ITEM (54) TITULO E AO QUADRO REIVINDICATORIO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/08/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 07/08/2021 |